Moderna Shares Fall 18% After Cancer Vaccine Data Leak Triggers Sell-Off

Key Takeaways

• Moderna shares closed 17.57% lower at $202.63 on October 22 after melanoma vaccine results appeared online ahead of their scheduled presentation.
• Intismeran plus Merck’s Keytruda reduced the risk of recurrence or death by 42% in Phase 3, compared with 49% in the earlier Phase 2b study.
• Investors now await the October 24 ESMO presentation and Moderna’s November 6 earnings, with attention on longer-term outcomes and commercial prospects.

Moderna Stock Slides Despite Positive Melanoma Results

source: googlefinance

Moderna shares fell sharply on Thursday, October 22, after the early release of detailed results from its experimental personalised cancer vaccine reignited debate over how much future success was already reflected in its valuation.

The stock closed at $202.63, down 17.57%, after touching an intraday low of $180.80—approximately 26% below its previous close. Nearly 50 million shares changed hands, more than three times the previous session’s volume.

Selling continued after the closing bell. Shares finished extended trading at $196.34, a further decline of 3.1%. Merck, Moderna’s development partner, ended the regular session approximately 1.8% lower.

The reaction followed positive clinical findings. The central question for investors was whether the strength of those results justified expectations built during Moderna’s substantial rally this year.

Early Disclosure Brings Forward a Major Catalyst

Detailed trial findings appeared on an oncology news website two days before their planned presentation at the European Society for Medical Oncology congress in Madrid.

Although the material was removed, the information circulated on social media. ESMO subsequently lifted the embargo, and Moderna and Merck released the detailed Phase 3 results on Thursday.

The unexpected timing brought forward a closely watched catalyst. Investors had been waiting for the numerical results since the companies announced in August that the study had met its main efficacy endpoints.

That earlier announcement established that the trial had succeeded. Thursday’s disclosure allowed investors to assess the size of the benefit more closely and reconsider assumptions about the treatment’s eventual market opportunity.

The abrupt release also meant trading initially unfolded while investors were assessing information outside the planned conference presentation and accompanying discussion.

What the 42% Risk Reduction Means

The Phase 3 INTerpath-001 study evaluated intismeran autogene alongside Keytruda in patients whose high-risk melanoma had been completely removed surgically.

The combination produced a hazard ratio of 0.58 for recurrence-free survival, representing a 42% relative reduction in the risk of cancer recurrence or death compared with Keytruda alone.

That figure describes a relative effect over the study period. It should not be interpreted as a 42-percentage-point improvement in survival or as proof that mortality alone fell by 42%.

The combination also reduced the risk of distant metastasis or death by 38%. Overall survival data remain immature, although the companies reported a favourable trend. Further follow-up is needed to establish the longer-term survival outcome.

These findings support continued development and regulatory discussions. They do not establish an approval date or resolve questions about the treatment’s eventual commercial performance.

Why the Phase 2b Comparison Needs Context

One focus of the market reaction was the difference between the Phase 3 headline result and the 49% reduction in recurrence or death previously reported from the smaller Phase 2b study.

The earlier figure came from approximately five years of follow-up in patients with resected stage III or IV melanoma. The Phase 3 study covered a broader stage IIB–IV population and had a shorter follow-up period.

Those differences limit a direct comparison. The numerical gap alone does not demonstrate that the treatment became less effective.

Investors will need to assess the full evidence, including the consistency of benefit across patient groups and how outcomes develop over time. Comparing two headline percentages provides only part of that assessment.

The distinction also matters for valuation. A successful late-stage trial can strengthen a development programme while leaving considerable uncertainty about adoption, revenue and the time required to reach the market.

Analyst Support Meets Elevated Valuation Expectations

Analyst responses highlighted the gap between a favourable clinical assessment and a favourable share-price reaction.

UBS suggested that elevated investor expectations could help explain the selling, while Jefferies described the findings as encouraging. These assessments support the interpretation that the decline reflected a reassessment of expectations following a powerful rally.

Moderna remained up roughly 600% for the year despite Thursday’s fall. Such a substantial advance creates a demanding backdrop for any subsequent announcement: confirmation of success may offer less upside when investors have already anticipated a strong result.

Published price targets also illustrate the valuation divide. Targets of $45 at Bernstein, $90 at TD Cowen and $80 at Citi were substantially below Thursday’s closing price.

Those targets reflect individual analysts’ assumptions and publication dates. They are estimates rather than predetermined destinations for the stock, and they may change as analysts incorporate the detailed results.

For market participants, the key issue is how the new evidence changes expectations for future earnings relative to the valuation already assigned to them.

ESMO Presentation and November Earnings Take Focus

The next major event is the formal ESMO presentation on Saturday, October 24.

Investors will look for a fuller discussion of the trial, the durability of benefit and the implications of immature overall survival data. Any assessment of potential applications in other cancers will also require caution: success in melanoma cannot establish efficacy across different tumour types.

Moderna’s third-quarter results follow on Friday, November 6, with a conference call scheduled for 8:00 a.m. ET.

That update will give investors another opportunity to examine financial performance, spending priorities and management’s development plans. The commercial questions extend beyond clinical efficacy to regulatory timing, manufacturing execution and the resources required to support a potential launch.

Moderna’s sell-off leaves investors weighing positive late-stage evidence against expectations accumulated during an exceptional rally. The ESMO presentation and November earnings will help determine whether the latest decline develops into a broader valuation reset or stabilises as the market absorbs the full results.

Get a generous deposit bonus on your first trade with Markets.com. Hurry—claim yours today!